- Home
- ANVS vs RAND Comparison
ANVS vs RAND Comparison
Compare ANVS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- RAND
- Stock Information
- Founded
- ANVS 2008
- RAND 1969
- Country
- ANVS United States
- RAND United States
- Employees
- ANVS N/A
- RAND N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- ANVS Health Care
- RAND Finance
- Exchange
- ANVS Nasdaq
- RAND Nasdaq
- Market Cap
- ANVS 54.6M
- RAND 57.6M
- IPO Year
- ANVS 2020
- RAND N/A
- Fundamental
- Price
- ANVS $2.64
- RAND $15.48
- Analyst Decision
- ANVS Strong Buy
- RAND
- Analyst Count
- ANVS 5
- RAND 0
- Target Price
- ANVS $30.25
- RAND N/A
- AVG Volume (30 Days)
- ANVS 570.5K
- RAND 6.1K
- Earning Date
- ANVS 08-14-2025
- RAND 08-05-2025
- Dividend Yield
- ANVS N/A
- RAND 7.47%
- EPS Growth
- ANVS N/A
- RAND 39.77
- EPS
- ANVS N/A
- RAND 3.12
- Revenue
- ANVS N/A
- RAND $8,499,970.00
- Revenue This Year
- ANVS N/A
- RAND N/A
- Revenue Next Year
- ANVS N/A
- RAND N/A
- P/E Ratio
- ANVS N/A
- RAND $4.98
- Revenue Growth
- ANVS N/A
- RAND 12.52
- 52 Week Low
- ANVS $1.11
- RAND $14.01
- 52 Week High
- ANVS $17.88
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- ANVS 54.28
- RAND 42.20
- Support Level
- ANVS $2.73
- RAND $15.15
- Resistance Level
- ANVS $3.08
- RAND $15.75
- Average True Range (ATR)
- ANVS 0.32
- RAND 0.52
- MACD
- ANVS -0.06
- RAND 0.14
- Stochastic Oscillator
- ANVS 29.41
- RAND 36.67
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.